open access

Vol 90, No 10 (2019)
ORIGINAL PAPERS Gynecology
Published online: 2019-10-31
Get Citation

GLUT 1 expression is a supportive mean in predicting prognosis and survival estimates of endometrial carcinoma

Mohamad Nidal Khabaz, Imtiaz Ahmad Qureshi, Jaudah Ahmad Al-Maghrabi
DOI: 10.5603/GP.2019.0102
·
Pubmed: 31686415
·
Ginekol Pol 2019;90(10):582-588.

open access

Vol 90, No 10 (2019)
ORIGINAL PAPERS Gynecology
Published online: 2019-10-31

Abstract

Objectives: This study will investigate the phenotype of Glucose transporter 1 (GLUT1) in endometrial cancer and the association of its expression with tumor’s clinicopathological factors.

Material and methods: Standard immunohistochemistry (IHC) staining protocol was utilized to identify the location and expression pattern of GLUT1 in a panel of 71 endometrial carcinomas compared to 30 normal tissues using tissue microarrays.

Results: High scores of GLUT1 staining are more frequent in cancer cases, it was recognized in 64 (90%) endometrial cancers and 12 (40%) control cases. Tissue histotype (cancer versus non-cancerous) was associated with IHC staining of GLUT1 (p = 0.000). Significant association between strong GLUT1 staining of malignant epithelial cells and stage of tumor (p = 0.000) was observed, advanced disease stages were more prevalent with high GLUT1 staining in malignant epithelial cells. There is also a significant association between high scores of GLUT1 staining and location of expression in transformed epithelium, cytoplasmic and membranous (p = 0.000), 100% of cases with cytoplasmic and membranous expression showed high GLUT1 staining scores. Considerable varied survival models were observed with positive GLUT 1 neoplasm regarding diagnosis, grade, stage, differentiation, and recurrence (p-values 0.000, 0.000, 0.000, 0.002, and 0.000 respectively). Survival estimates are considerably healthier in positive GLUT1 staining cases of endometrial carcinoma, which have low grade, low stage and no recurrence.

Conclusions: GLUT1 expression has been found upregulated in endometrial carcinoma. IHC staining of GLUT1 can be a supportive mean in predicting prognosis and survival estimates of endometrial carcinoma with specific clinical factors.

Abstract

Objectives: This study will investigate the phenotype of Glucose transporter 1 (GLUT1) in endometrial cancer and the association of its expression with tumor’s clinicopathological factors.

Material and methods: Standard immunohistochemistry (IHC) staining protocol was utilized to identify the location and expression pattern of GLUT1 in a panel of 71 endometrial carcinomas compared to 30 normal tissues using tissue microarrays.

Results: High scores of GLUT1 staining are more frequent in cancer cases, it was recognized in 64 (90%) endometrial cancers and 12 (40%) control cases. Tissue histotype (cancer versus non-cancerous) was associated with IHC staining of GLUT1 (p = 0.000). Significant association between strong GLUT1 staining of malignant epithelial cells and stage of tumor (p = 0.000) was observed, advanced disease stages were more prevalent with high GLUT1 staining in malignant epithelial cells. There is also a significant association between high scores of GLUT1 staining and location of expression in transformed epithelium, cytoplasmic and membranous (p = 0.000), 100% of cases with cytoplasmic and membranous expression showed high GLUT1 staining scores. Considerable varied survival models were observed with positive GLUT 1 neoplasm regarding diagnosis, grade, stage, differentiation, and recurrence (p-values 0.000, 0.000, 0.000, 0.002, and 0.000 respectively). Survival estimates are considerably healthier in positive GLUT1 staining cases of endometrial carcinoma, which have low grade, low stage and no recurrence.

Conclusions: GLUT1 expression has been found upregulated in endometrial carcinoma. IHC staining of GLUT1 can be a supportive mean in predicting prognosis and survival estimates of endometrial carcinoma with specific clinical factors.

Get Citation

Keywords

GLUT1; immunohistochemistry; endometrial carcinoma

About this article
Title

GLUT 1 expression is a supportive mean in predicting prognosis and survival estimates of endometrial carcinoma

Journal

Ginekologia Polska

Issue

Vol 90, No 10 (2019)

Pages

582-588

Published online

2019-10-31

DOI

10.5603/GP.2019.0102

Pubmed

31686415

Bibliographic record

Ginekol Pol 2019;90(10):582-588.

Keywords

GLUT1
immunohistochemistry
endometrial carcinoma

Authors

Mohamad Nidal Khabaz
Imtiaz Ahmad Qureshi
Jaudah Ahmad Al-Maghrabi

References (27)
  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1): 7–30.
  2. Alrawaji AI, Al-Shahrani ZS, Alzahrani W, et al. Cancer Incidence Report Saudi Arabia 2015, Saudi Cancer Registry 2018. https://nhic.gov.sa/eServices/Pages/TumorRegistration.aspx.
  3. Piulats JM, Guerra E, Gil-Martín M, et al. Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol. 2017; 145(1): 200–207.
  4. Sohaib SA, Houghton SL, Meroni R, et al. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol. 2007; 62(1): 28–34; discussion 35.
  5. Odagiri T, Watari H, Hosaka M, et al. Multivariate survival analysis of the patients with recurrent endometrial cancer. J Gynecol Oncol. 2011; 22(1): 3–8.
  6. Żyła MM, Wilczyński JR, Kostrzewa M, et al. The significance of markers in the diagnosis of endometrial cancer. Prz Menopauzalny. 2016; 15(3): 176–185.
  7. Noguchi Y, Saito A, Miyagi Y, et al. Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Letters. 2000; 154(2): 175–182.
  8. Wang Ji, Ye C, Chen C, et al. Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017; 8(10): 16875–16886.
  9. Yu M, Yongzhi H, Chen S, et al. The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis. Oncotarget. 2017; 8(26): 43356–43367.
  10. Zhang Bo, Xie Z, Li B. The clinicopathologic impacts and prognostic significance of GLUT1 expression in patients with lung cancer: A meta-analysis. Gene. 2019; 689: 76–83.
  11. Němejcová K, Rosmusová J, Bártů M, et al. Expression of Glut-1 in Normal Endometrium and Endometrial Lesions: Analysis of 336 Cases. Int J Surg Pathol. 2017; 25(5): 389–396.
  12. Al-Sharaky DR, Abdou AG, Wahed MM, et al. HIF-1α and GLUT-1 Expression in Atypical Endometrial Hyperplasia, Type I and II Endometrial Carcinoma: A Potential Role in Pathogenesis. J Clin Diagn Res. 2016; 10(5): EC20–EC27.
  13. Canpolat T, Ersöz C, Uğuz A, et al. GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma. Turk Patoloji Derg. 2016; 32(3): 141–147.
  14. Ma X, Hui Y, Lin Li, et al. Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues. Pak J Med Sci. 2015; 31(2): 280–284.
  15. Sadlecki P, Bodnar M, Grabiec M, et al. The role of Hypoxia-inducible factor-1 α , glucose transporter-1, (GLUT-1) and carbon anhydrase IX in endometrial cancer patients. Biomed Res Int. 2014; 2014: 616850.
  16. Xiong Y, Xiong YY, Zhou YF. Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma. Eur J Gynaecol Oncol. 2010; 31(2): 160–164.
  17. Ashton-Sager A, Paulino AFG, Afify AM. GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma. Appl Immunohistochem Mol Morphol. 2006; 14(2): 187–192.
  18. Sebastiani V, Visca P, Botti C, et al. Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. Gynecol Oncol. 2004; 92(1): 101–105.
  19. Wang BY, Kalir T, Sabo E, et al. Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia. Cancer. 2000; 88(12): 2774–2781.
  20. Anagnostou E, Miliaras D, Meditskou S, et al. Immunohistochemical investigation of metabolic markers fatty acid synthase (FASN) and glucose transporter 1 (GLUT1) in normal endometrium, endometrial hyperplasia, and endometrial malignancy. Hippokratia. 2017; 21(4): 169–174.
  21. Goldman NA, Katz EB, Glenn AS, et al. GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol. 2006; 19(11): 1429–1436.
  22. Wahl H, Daudi S, Kshirsagar M, et al. Expression of metabolically targeted biomarkers in endometrial carcinoma. Gynecol Oncol. 2010; 116(1): 21–27.
  23. Al-Maghrabi J, Emam E, Gomaa W, et al. c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence. BMC Cancer. 2015; 15: 676.
  24. Warburg O. On the Origin of Cancer Cells. Science. 1956; 123(3191): 309–314.
  25. Liberti MV, Locasale JW, Liberti MV, et al. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2016; 41(3): 211–218.
  26. Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998; 83(1): 34–40.
  27. Zhao ZX, Lu LW, Qiu J, et al. Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis. Oncotarget. 2018; 9(2): 2728–2738.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl